Stock Events

Stock Events

Crescent Biopharma 

$12.89
73
+$0.31+2.46% 15:22 Today

Statistics

Day High
13.17
Day Low
12.5
52W High
27.41
52W Low
8.72
Volume
43,543
Avg. Volume
372,492
Mkt Cap
478.82M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jan 2023
$3.60
Sep 2022
$21.45
Aug 2015
$8.54
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Nov 18Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.1
-0.06
-0.01
0.04
Expected EPS
-0.1042069644
Actual EPS
N/A

Financials

-1,419.61%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
10.84MRevenue
-153.94MNet Income

Analyst Ratings

$31.50Average Price Target
The highest estimate is ⁦36.00⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CBIO. It's not an investment recommendation.
Tesla
8
TSLA
Netflix
8
NFLX
Microsoft
7
MSFT
Amazon
7
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is involved in gene editing for genetic diseases, which could compete with GlycoMimetics' drug development programs.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, competing in the broader market for rare diseases.
Novartis
NVS
Mkt Cap268B
Novartis offers a wide range of pharmaceutical products, including treatments for conditions that GlycoMimetics targets.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the rare disease space with GlycoMimetics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetic diseases, potentially competing with GlycoMimetics' therapeutic approaches.
Sarepta Therapeutics
SRPT
Mkt Cap1.85B
Sarepta Therapeutics develops RNA-based therapeutics for rare diseases, which could compete with GlycoMimetics' products.
AMGEN
AMGN
Mkt Cap217.9B
Amgen is a biotechnology company with a broad portfolio, including treatments for conditions that GlycoMimetics may target.

About

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Show More
CEO
Joshua T. Brumm
Employees
44
Country
United States
ISIN
KYG2545C1042
WKN
000A3EE5F

Listings

STU
DE
C68.STU
F
DE
C68.F
MU
DE
C68.MU
BOATS
BOATS
CBIO.BOATS

0 Comments

Share your thoughts

FAQs

What is Crescent Biopharma stock price today?▼
The current price of CBIO is $12.89 USD — it has increased by +2.46% in the past 24 hours. Watch Crescent Biopharma stock price performance more closely on the chart.
What is Crescent Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Crescent Biopharma stocks are traded under the ticker CBIO.
Is Crescent Biopharma stock price growing?▼
CBIO stock has fallen by -8.14% compared to the previous week, the month change is a -31.01% fall, over the last year Crescent Biopharma has showed a +14.88% increase.
What is Crescent Biopharma market cap?▼
Today Crescent Biopharma has the market capitalization of 478.82M
When is the next Crescent Biopharma earnings date?▼
Crescent Biopharma is going to release the next earnings report on November 5, 2026.
What were Crescent Biopharma earnings last quarter?▼
CBIO earnings for the last quarter are -0.74 USD per share, whereas the estimation was -0.74 USD resulting in a -0.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Crescent Biopharma revenue for the last year?▼
Crescent Biopharma revenue for the last year amounts to 10.84M USD.
What is Crescent Biopharma net income for the last year?▼
CBIO net income for the last year is -153.94M USD.
Does Crescent Biopharma pay dividends?▼
Yes, CBIO dividends are paid monthly. The last dividend per share was 3.6 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Crescent Biopharma have?▼
As of October 15, 2026, the company has 44 employees.
In which sector is Crescent Biopharma located?▼
Crescent Biopharma operates in the Health & Wellness sector.
When did Crescent Biopharma complete a stock split?▼
The last stock split for Crescent Biopharma was on June 16, 2025 with a ratio of 1:100.
Where is Crescent Biopharma headquartered?▼
Crescent Biopharma is headquartered in WALTHAM, United States.